Item 8.01. Other Events.
On September 6, 2022, Spero Therapeutics, Inc. issued a press release announcing
an update on its tebipenem HBr program following the receipt of minutes from a
recent Type A meeting with the U.S. Food and Drug Administration, discussing
steps required for resubmission of the New Drug Application for tebipenem HBr
for the treatment of complicated urinary tract infection, including
pyelonephritis. A copy of the press release is filed as Exhibit 99.1 hereto and
is incorporated into this Item 8.01 by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release, dated September 6, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses